ARTICLE | Clinical News
ALB-127158: Phase I started
August 2, 2010 7:00 AM UTC
Albany Molecular began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate oral ALB-127158(a) in 62 healthy volunteers and patients. The 2-part study will initially eva...